The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation
Open accessAbstract
Noonan syndrome is a developmental disorder with dysmorphic facies, short stature, cardiac defects, and skeletal anomalies, which can be caused by missense PTPN11 mutations. PTPN11 encodes Src homology 2 domain-containing tyrosine phosphatase 2 (SHP2 or SHP-2), a protein tyrosine phosphatase that acts in signal transduction downstream to growth factor, hormone, and cytokine receptors. We compared the functional effects of three Noonan syndrome-causative PTPN11 mutations on SHP2's phosphatase activity, interaction with a binding partner, and signal transduction. All SHP2 mutants had significantly increased basal phosphatase activity compared to wild type, but that activity varied significantly between mutants and was further increased after epidermal growth factor stimulation. Cells expressing SHP2 mutants had prolonged extracellular signal-regulated kinase 2 activation, which was ligand-dependent. Binding of SHP2 mutants to Grb2-associated binder-1 was increased and sustained, and tyrosine phosphorylation of both proteins was prolonged. Coexpression of Grb2-associated binder-1-FF, which lacks SHP2 binding motifs, blocked the epidermal growth factor-mediated increase in SHP2's phosphatase activity and resulted in a dramatic reduction of extracellular signal-regulated kinase 2 activation. Taken together, these results document that Noonan syndrome-associated PTPN11 mutations increase SHP2's basal phosphatase activity, with greater activation when residues directly involved in binding at the interface between the N-terminal Src homology 2 and protein tyrosine phosphatase domains are altered. The SHP2 mutants prolonged signal flux through the RAS/mitogen-activated protein kinase (ERK2/MAPK1) pathway in a ligand-dependent manner that required docking through Grb2-associated binder-1 (GAB1), leading to increased cell proliferation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The ‘Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling
Neel, B. G., Gu, H., & Pao, L. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00091-4 · Cited by 1,249
Shp-2 Tyrosine Phosphatase: Signaling One Cell or Many
Feng, G.-S. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4668 · Cited by 285
Cited by
Germline gain-of-function mutations in SOS1 cause Noonan syndrome
Roberts, A. E., Araki, T., Swanson, K. D., Montgomery, K. T., Schiripo, T. A., Joshi, V. A., Li, L., Yassin, Y., Tamburino, A. M., Neel, B. G., et al. (2007) · Nature Genetics · doi:10.1038/ng1926 · Cited by 605
Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome
Tartaglia, M., Pennacchio, L. A., Zhao, C., Yadav, K. K., Fodale, V., Sarkozy, A., Pandit, B., Oishi, K., Martinelli, S., Schackwitz, W., et al. (2007) · Nature Genetics · doi:10.1038/ng1939 · Cited by 586
Self-citationGermline gain-of-function mutations in RAF1 cause Noonan syndrome
Razzaque, M. A., Nishizawa, T., Komoike, Y., Yagi, H., Furutani, M., Amo, R., Kamisago, M., Momma, K., Katayama, H., Nakagawa, M., et al. (2007) · Nature Genetics · doi:10.1038/ng2078 · Cited by 498
Heart Valve Development: Regulatory Networks in Development and Disease
Combs, M. D., & Yutzey, K. E. (2009) · Circulation Research · doi:10.1161/circresaha.109.201566 · Cited by 455
Araki, T., Mohi, M. G., Ismat, F. A., Bronson, R. T., Williams, I. R., Kutok, J. L., Yang, W., Pao, L. I., Gilliland, D. G., Epstein, J. A., et al. (2004) · Nature Medicine · doi:10.1038/nm1084 · Cited by 420
Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease
Tartaglia, M., Martinelli, S., Stella, L., Bocchinfuso, G., Flex, E., Cordeddu, V., Zampino, G., van der Burgt, I., Palleschi, A., Petrucci, T. C., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/499925 · Cited by 415
Self-citationCell Biology of Cardiac Cushion Development
Person, A. D., Klewer, S. E., & Runyan, R. B. (2005) · International Review of Cytology · doi:10.1016/s0074-7696(05)43005-3 · Cited by 372
The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders
Aoki, Y., Niihori, T., Narumi, Y., Kure, S., & Matsubara, Y. (2008) · Human Mutation · doi:10.1002/humu.20748 · Cited by 365
NOONAN SYNDROME AND RELATED DISORDERS: Genetics and Pathogenesis
Tartaglia, M., & Gelb, B. D. (2005) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.6.080604.162305 · Cited by 355
Self-citationGenetics of Myeloid Malignancies: Pathogenetic and Clinical Implications
Fröhling, S., Scholl, C., Gilliland, D. G., & Levine, R. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.010 · Cited by 353
PTPN11 (Shp2) Mutations in LEOPARD Syndrome Have Dominant Negative, Not Activating, Effects
Kontaridis, M. I., Swanson, K. D., David, F. S., Barford, D., & Neel, B. G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513068200 · Cited by 338
Mitogen-Activated Protein Kinases in Heart Development and Diseases
Wang, Y. (2007) · Circulation · doi:10.1161/circulationaha.106.679589 · Cited by 315
Diverse Biochemical Properties of Shp2 Mutants
Keilhack, H., David, F. S., McGregor, M., Cantley, L. C., & Neel, B. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504699200 · Cited by 298
Tartaglia, M. (2004) · Blood · doi:10.1182/blood-2003-11-3876 · Cited by 289
Self-citationThe Tyrosine Phosphatase Shp2 in Development and Cancer
(2010) · Advances in Cancer Research · doi:10.1016/s0065-230x(10)06002-1 · Cited by 277
Marin, T. M., Keith, K., Davies, B., Conner, D. A., Guha, P., Kalaitzidis, D., Wu, X., Lauriol, J., Wang, B., Bauer, M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44972 · Cited by 282
Discovery of a Novel Shp2 Protein Tyrosine Phosphatase Inhibitor
Chen, L., Sung, S.-S., Yip, M. L. R., Lawrence, H. R., Ren, Y., Guida, W. C., Sebti, S. M., Lawrence, N. J., & Wu, J. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.025536 · Cited by 279
Self-citationThe neural crest in cardiac congenital anomalies
Keyte, A., & Hutson, M. R. (2012) · Differentiation · doi:10.1016/j.diff.2012.04.005 · Cited by 259
Protein tyrosine phosphatase SHP-2: A proto-oncogene product that promotes Ras activation
Matozaki, T., Murata, Y., Saito, Y., Okazawa, H., & Ohnishi, H. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01257.x · Cited by 240
SHP2 sails from physiology to pathology
Tajan, M., de Rocca Serra, A., Valet, P., Edouard, T., & Yart, A. (2015) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2015.08.005 · Cited by 232
Song, Y., Zhao, M., Zhang, H., & Yu, B. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107966 · Cited by 125
Molecular Basis of Gain-of-Function LEOPARD Syndrome-Associated SHP2 Mutations
Yu, Z.-H., Zhang, R.-Y., Walls, C. D., Chen, L., Zhang, S., Wu, L., Liu, S., & Zhang, Z.-Y. (2014) · Biochemistry · doi:10.1021/bi5002695 · Cited by 87
Transgenic Drosophila models of Noonan syndrome causing PTPN11 gain-of-function mutations
Oishi, K., Gaengel, K., Krishnamoorthy, S., Kamiya, K., Kim, I.-K., Ying, H., Weber, U., Perkins, L. A., Tartaglia, M., Mlodzik, M., et al. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddi471 · Cited by 81
Self-citationNiimi, H., Harada, H., Harada, Y., Ding, Y., Imagawa, J., Inaba, T., Kyo, T., & Kimura, A. (2006) · Leukemia · doi:10.1038/sj.leu.2404136 · Cited by 69
Huang, W., Saberwal, G., Horvath, E., Zhu, C., Lindsey, S., & Eklund, E. A. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00036-06 · Cited by 41
Wang, R.-R., Liu, W.-S., Zhou, L., Ma, Y., & Wang, R.-L. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1613266 · Cited by 21
Metadata
- Authors
- Fragale, A., Tartaglia, M., Wu, J., & Gelb, B. D.
- Venue
- Human Mutation
- Publisher
- Hindawi Limited
- Published
- 2004
- Volume
- 23
- Issue
- 3
- Pages
- 267-277
- ISSN
- 1059-7794 (ISSN-L)
- 1098-1004
- OpenAlex
- W1988127794
- Cited by
- 194
- References
- 2
- FWCI
- 5.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.